AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00562224
Drug: PCI-24781
RxNorm normalized name: PCI-27483
DrugBank: PCI-27483 (DB13000)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up to 7 cohorts will receive PCI-24781 orally at doses starting at 30 mg/m2 three times a day approximately 4 hours apart (TID), up to 90 mg/m2, administered 5 days/week during the first 21 days of each 28 day cycle until MTD is reached. If a dose limiting toxicity (DLT) occurs, then the next cohort will receive PCI-24781 twice a day approximately 4 hours apart (BID). If a DLT occurs on the BID schedule, the subsequent cohort will receive PCI-24781 BID for 7 days every other week (2 times in a 28 day cycle). If a DLT occurs on this dosing schedule, then the next cohort will receive PCI-24781 BID for 5 days/week every other week (2 times in a 28 day cycle) until the maximum tolerated dose is reached.
Trial: NCT00992108
Drug: lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1cc 1%
Trial: NCT03379168
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sterile saline injection will act as a placebo group.
Trial: NCT03961672
Drug: Duvelisib
RxNorm normalized name: Duvelisib
DrugBank: Duvelisib (DB11952)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT02040376
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin doses will be 500 mg/m2 po daily given in 2 doses for one week and if there are no concerns increased to 1000 mg/m2 po daily given in 2 doses for the rest of the 12 week trial. The investigators will use the closest dose according to body surface area (250-500-750-1000) BID.
Trial: NCT02381561
Drug: Ropidoxuridine
RxNorm normalized name: Ropidoxuridine
DrugBank: Ropidoxuridine (DB06485)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00607776
Drug: Systane
RxNorm normalized name: Systane
DrugBank: Propylene glycol (DB01839)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drops
Trial: NCT00646165
Drug: Forodesine
RxNorm normalized name: Forodesine
DrugBank: Forodesine (DB06185)
FDA approved: no
EMA approved: no
PMDA approved: yes
Trial: NCT02435186
Drug: p53 gene
RxNorm normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: p53 gene will be given intraperitoneally.
Trial: NCT02435186
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg/m\^2 cisplatin will be given intraperitoneally.
Trial: NCT02435186
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel (175 mg/m2, 3 h) will be given by iv
Trial: NCT02759614
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab15mg/kg by intravenous drip infusion on day 1 of a 21-day (within 3 days) cycle and Erlotinib orally once daily at 150mg/day
Trial: NCT02759614
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erlotinib 150mg, orally once a day
Trial: NCT04106557
Drug: Gaboxadol
RxNorm normalized name: Gaboxadol
DrugBank: Gaboxadol (DB06554)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OV101 versus placebo once daily at bedtime for 12 weeks
Trial: NCT03175367
Drug: Evinacumab
RxNorm normalized name: Evinacumab
DrugBank: Evinacumab (DB15354)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: SC or IV administration
Trial: NCT03512821
Drug: Ursodiol 500 MG
RxNorm normalized name: ursodiol 500 MG
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ursodiol 500mg tablets followed by Urso Forte 500mg tablets
Trial: NCT03512821
Drug: Urso Forte 500Mg Tablet
RxNorm normalized name: Urso Forte 500mg Tablet
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urso forte 500mg tablets followed by Ursodiol 500mg tablets
Trial: NCT03123692
Drug: Emeramide
RxNorm normalized name: Emeramide
DrugBank: Emeramide (DB12192)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipophilic, membrane passing Metal chelator and anti oxidant
Trial: NCT01533207
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01533207
Drug: Gemcitabine Hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01803451
Drug: exendin-(9-39)
RxNorm normalized name: Exendin 4
DrugBank: Avexitide (DB14806)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hyperglycemic clamp-meal tolerance test is designed to assess insulin secretion before and after meal ingestion
Trial: NCT01803451
Drug: exendin -(9-39)
RxNorm normalized name: Exendin 4
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2-day meal tolerance tests with labeled oral and IV glucose using exendin-(9-39) infusion are designed to evaluate the role of GLP-1 signaling on glucose tolerance and glucose kinetics.
Trial: NCT03320707
Drug: Daratumumab
RxNorm normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single SC dose of daratumumab will be administered in each of 8 dose cohorts.
Trial: NCT01918527
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenously on day 1: 130 mg/m2 q3w
Trial: NCT01181063
Drug: Budesonide/formoterol 320/9 μg and 400/12 μg inhalers
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide/formoterol 320/9 μg and 400/12 μg in different kind of inhalers and Symbicort Turbuhaler forte 320/9 μg. Ech subject will be randomly allocation to 4 of 5 products, a single dose administration of each product
Trial: NCT01801163
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorafenib x 2 weeks followed by Stereotactic Radiotherapy and then sorafenib until disease progression.
Trial: NCT00381810
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab will be supplied as a liquid for intravenous infusion.
Trial: NCT00381810
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00381810
Drug: Diphenhydramine
RxNorm normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02770014
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04445285
Drug: 0.9%sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo of 0.9% sodium chloride every 24 hours for five (5) consecutive days; a total of 5 doses
Trial: NCT02257138
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02257138
Drug: Ruxolitinib Phosphate
RxNorm normalized name: Ruxolitinib Phosphate
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04420234
Drug: narfurine hydrochloride orally disintegrating tablets
RxNorm normalized name: diphenhydramine hydrochloride Disintegrating Oral Tablet
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects swallowed 2 tablets of test drug (2.5 µg/tablet) with saliva at about 8:00 AM on D1; swallowed 2 tablets of test drug (2.5 µg/tablet) with saliva at about 8:00 AM starting on D4. Dosing for 7 consecutive days (D10 last dose in the morning).
Trial: NCT00005942
Drug: liposomal daunorubicin citrate
RxNorm normalized name: daunorubicin citrate liposome
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00005942
Drug: semaxanib
RxNorm normalized name: Semaxanib
DrugBank: Semaxanib (DB06436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02675465
Drug: AT2221
RxNorm normalized name: AT2221
DrugBank: Miglustat (DB00419)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02043756
Drug: Mitoxantrone Hydrochloride Liposome
RxNorm normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6-16mg/m2, IV ,one time of each 28 day cycle,3 cycles
Trial: NCT02043756
Drug: Mitoxantrone
RxNorm normalized name: Mitoxantrone
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10mg/m2, IV ,on day 1 of each 28 day,3 cycles
Trial: NCT00915252
Drug: azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Starting dose has been determined during run-in dose finding part of the study. Starting dose of the interventional drug is 75 mg/m²/d. Application form:~During induction therapy phase: i.v. on days -5--1 before standard chemotherapy for 1 or 2 cycles, During consolidation therapy: s.c. on days -5--1 before standard chemotherapy (2 cycles).~During maintenance therapy: s.c. on days 1-5 on a 28day cycle till maximum one year after start of first induction therapy.
Trial: NCT00915252
Drug: standard chemotherapy (7+3 scheme): Daunorubicin, Cytarabine
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Induction therapy:~Daunorubicin 60mg/m²/d i.v.on days 3,4,5 AraC 100mg/m²/d i.v. on days 1-7~Consolidation therapy:~AraC 1g/m² twice a day on day 1,3,5
Trial: NCT03537989
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To reduce the volume of saline administered during surgery of the colon and the rectum
Trial: NCT03379181
Drug: Propranolol
RxNorm normalized name: Propranolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients receive a single dose of 80 mg propranolol p.o.
Trial: NCT01310777
Drug: Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01310777
Drug: Brinzolamide 1% ophthalmic suspension
RxNorm normalized name: Brinzolamide 1% Ophthalmic Suspension
DrugBank: Brinzolamide (DB01194)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01310777
Drug: Brimonidine tartrate 0.2% ophthalmic solution
RxNorm normalized name: Brimonidine Tartrate 0.2% Ophthalmic Solution
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02203396
Drug: rabbit ATG, Cyclosporine, Levamisole
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rATG is administered at a dose of 1.97 mg/kg/day for 9 days CSA is administered orally at a dose of 3 mg/kg qod Levamisole is administered orally at a dose of 2.5 mg/kg qod. The CSA and LMS is designed to alternately every other day.
Trial: NCT04623931
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT01350947
Drug: 5-Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered on Days 1-7 of each Cycle.~Subcutaneous administration:~To provide a homogeneous suspension, the contents of the syringe must be re-suspended by inverting the syringe 2-3 times and vigorously rolling the syringe between the palms for 30 seconds immediately prior to administration.~The 5-azacitidine suspension is administered subcutaneously.~Intravenous Administration:~5-Azacitidine solution is administered intravenously. Administer the total dose over a period of 10-40 minutes.
Trial: NCT03365882
Drug: Irinotecan Hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03781986
Drug: APG-115
RxNorm normalized name: APGA
DrugBank: Aminopterin (DB08878)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APG-115 at 150mg (or lower, if dose is reduced) is taken orally every other day through day 13 of each cycle. Cycle length 21 days.
Trial: NCT03781986
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin is given IV at AUC=4.5 on day 1 of each cycle. Cycle length 21 days.
Trial: NCT03932344
Drug: Anakinra
RxNorm normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Anakinra according to prescription
Trial: NCT03939624
Drug: Sodium-glucose cotransporter 2 (SGLT2) inhibitors
RxNorm normalized name: glucose / sodium chloride
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exposure to SGLT2 will be defined as a prescription for a SGLT2 inhibitor alone (canagliflozin, dapagliflozin, empagliflozin) or in combination with non-DPP4 inhibitor drugs at cohort entry date.
Trial: NCT03939624
Drug: Dipeptidyl peptidase-4 (DPP-4) inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exposure to DPP-4 will be defined as a prescription for a DPP-4 inhibitor (alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin) alone or in combination with non-SGLT2 inhibitor drugs at cohort entry date.
Trial: NCT04418024
Drug: AG10
RxNorm normalized name: JAG101
DrugBank: JAG101 (DB18321)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TTR stabilizer administered orally twice daily (BID)
Trial: NCT02435212
Drug: Deferasirox granule formulation
RxNorm normalized name: deferasirox Granule Product
DrugBank: Deferasirox (DB01609)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Deferasirox granules will be provided as stick packs containing 90 mg, 180 mg and 360 mg granules for oral use and will be administered based on body weight.
Trial: NCT02435212
Drug: Deferasirox DT formulation
RxNorm normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Deferasirox DT will be provided as 125 mg, 250 mg and 500 mg dispersible tablets for oral use and will be administered based on body weight.
Trial: NCT01856270
Drug: Amitriptyline
RxNorm normalized name: Amitriptyline
DrugBank: Amitriptyline (DB00321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants with headache will be enrolled within the first 12 weeks after injury and will be randomly assigned to 2 groups (see Table 1 for summary of protocol). Group 1 will be assessed within 3 months of injury (baseline, Day 0) (when they will receive their initial ramp-up dosage containers; see Table 2 for dosing), Day 30 and Day 60 (to monitor compliance and distribute study drug), and for final outcome on Day 90. Group 2 will be assessed within 3 months of injury (baseline, Day 0) but will not receive medication until their Day 30 visit. Those in group 2 who report headache at Day 30 will receive their initial dosage container and will then be reassessed at Day 60 (to monitor compliance and distribute study drug) and Day 90 (final outcome).
Trial: NCT02731638
Drug: Intrastromal voriconazole
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive three intrastromal voriconazole injections over 10 days. Intrastromal voriconazole injection is a routine procedure performed by Aravind Eye Hospital for fungal keratitis.
Trial: NCT02731638
Drug: Natamycin
RxNorm normalized name: Natamycin
DrugBank: Natamycin (DB00826)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive topical 5% natamycin drops hourly for 3 days.
Trial: NCT03169777
Drug: 5-Fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluoro-2,4 (1H,3H)-pyrimidinedione
Trial: NCT03169777
Drug: fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 7-alpha-\[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl\]estra-1,3,5-(10)- triene-3,17-beta-diol
Trial: NCT03169777
Drug: nab paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
Trial: NCT03169777
Drug: Lovaza
RxNorm normalized name: Lovaza
DrugBank: Omega-3-acid ethyl esters (DB09539)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3-acid ethyl esters
Trial: NCT03169777
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum
Trial: NCT03538041
Drug: Parsaclisib
RxNorm normalized name: Parsaclisib
DrugBank: Parsaclisib (DB14867)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parsaclisib administered orally.
Trial: NCT00000211
Drug: Buprenorphine
RxNorm normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04439539
Drug: JNJ-73763989
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-73763989 injection will be administered subcutaneously.
Trial: NCT04439539
Drug: PegIFN-alpha-2a
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PegIFN-alpha-2a injection will be administered subcutaneously.
Trial: NCT04439539
Drug: Tenofovir disoproxil
RxNorm normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenofovir disoproxil film-coated tablet will be administered orally.
Trial: NCT04439539
Drug: Tenofovir alafenamide
RxNorm normalized name: Tenofovir Alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tenofovir alafenamide film-coated tablet will be administered orally.
Trial: NCT04439539
Drug: JNJ-56136379
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-56136379 will be administered orally.
Trial: NCT00336063
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given SC
Trial: NCT00336063
Drug: Vorinostat
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00250042
Drug: Gleevec and Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pts. who fit the inclusion criteria, \& were on imatinib, 400 mg/day, will be treated with a month of imatinib at 800 mg/d in divided doses (400mg bid) \& then started on arsenic trioxide. Pts. already on imatinib 800 mg/day may be started on arsenic trioxide. Pts. unable to tolerate 800 mg/d should be treated at the max. dose tolerated above 400 mg/d. A total of 16 weeks of arsenic trioxide treatment will be administered (15 weeks of maintenance). Pts. are to continue on imatinib 800 mg/day,(or the max. tolerated dose) while receiving the arsenic trioxide. If a pt. has been taken off the arsenic trioxide, they should be continued on gleevec 800 mg per day (or the maximum tolerated dose) until there is evidence of progression of disease.
Trial: NCT04111458
Drug: BI 1701963
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT04111458
Drug: Trametinib
RxNorm normalized name: Trametinib
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablet
Trial: NCT02227914
Drug: Oprozomib
RxNorm normalized name: Oprozomib
DrugBank: Oprozomib (DB11991)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study subjects will receive oprozomib tablets once a day on Days 1, 2, 8, 9, 15, 16, 22 and 23 of a 28 day cycle
Trial: NCT02227914
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study subjects will receive sorafenib tablets twice a day for Days 1-28
Trial: NCT00611936
Drug: Atomoxetine
RxNorm normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20mg maximum of d-amphetamine
Trial: NCT04160117
Drug: Colchicine 0.6 mg
RxNorm normalized name: colchicine 0.6 MG
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: p.o. twice daily for 10 days after catheter ablation for atrial fibrillation
Trial: NCT04439227
Drug: Adavosertib
RxNorm normalized name: Adavosertib
DrugBank: Adavosertib (DB11740)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02226341
Drug: CellCept
RxNorm normalized name: Cellcept
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: For both arms:~CellCept 3 grams daily, oral, from Week 0-24 CellCept 2 grams daily, oral, from Week 25-144
Trial: NCT02226341
Drug: ACTHar gel
RxNorm normalized name: Acthar Gel
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arm 1: 80 U biw, subcutaneous, for 3 months. Optionally additional 3 months of 80 U biw if a patient has partial response.~Arm 2: 80 U qod, subcutaneous, for 1 month, then 80 U biw, subcutaneous, for 2 months. Optionally additional 3 months of 80 U biw if a patient has partial response.
Trial: NCT02122562
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment